These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 19148563

  • 1. LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men.
    Kruk M, Ralston SH, Albagha OM.
    Calcif Tissue Int; 2009 Mar; 84(3):171-9. PubMed ID: 19148563
    [Abstract] [Full Text] [Related]

  • 2. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 3. Low-density lipoprotein receptor-related protein 5 polymorphisms are associated with bone mineral density in Greek postmenopausal women: an interaction with calcium intake.
    Stathopoulou MG, Dedoussis GV, Trovas G, Katsalira A, Hammond N, Deloukas P, Lyritis GP.
    J Am Diet Assoc; 2010 Jul; 110(7):1078-83. PubMed ID: 20630166
    [Abstract] [Full Text] [Related]

  • 4. Association of the A1330V and V667M polymorphisms of LRP5 with bone mineral density in Greek peri- and postmenopausal women.
    Markatseli AE, Hatzi E, Bouba I, Georgiou I, Challa A, Tigas S, Tsatsoulis A.
    Maturitas; 2011 Oct; 70(2):188-93. PubMed ID: 21840657
    [Abstract] [Full Text] [Related]

  • 5. Genetic variation at the low-density lipoprotein receptor-related protein 5 (LRP5) locus modulates Wnt signaling and the relationship of physical activity with bone mineral density in men.
    Kiel DP, Ferrari SL, Cupples LA, Karasik D, Manen D, Imamovic A, Herbert AG, Dupuis J.
    Bone; 2007 Mar; 40(3):587-96. PubMed ID: 17137849
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE, Fosamax Actonel Comparison Trial Investigators.
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S, Manguso F, Orio F, Russo T, Oppedisano R, Sacchinelli A, Falbo A, Tolino A, Zullo F, Mastrantonio P.
    Menopause; 2008 Jan; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
    Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP.
    J Bone Miner Res; 2000 Jun; 15(6):1006-13. PubMed ID: 10841169
    [Abstract] [Full Text] [Related]

  • 10. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL, He JW, Qin YJ, Huang QR, Liu YJ, Hu YQ, Li M.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [Abstract] [Full Text] [Related]

  • 11. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME.
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
    Hooper MJ, Ebeling PR, Roberts AP, Graham JJ, Nicholson GC, D'Emden M, Ernst TF, Wenderoth D.
    Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H, Risedronate Phase III Research Group.
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [Abstract] [Full Text] [Related]

  • 18. Analysis of association of LRP5, LRP6, SOST, DKK1, and CTNNB1 genes with bone mineral density in a Slovenian population.
    Mencej-Bedrac S, Prezelj J, Kocjan T, Komadina R, Marc J.
    Calcif Tissue Int; 2009 Dec; 85(6):501-6. PubMed ID: 19898734
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Polymorphism of LRP5, but not of TNFRSF11B, is associated with a decrease in bone mineral density in postmenopausal Maya-Mestizo women.
    Canto-Cetina T, Polanco Reyes L, González Herrera L, Rojano-Mejía D, Coral-Vázquez RM, Coronel A, Canto P.
    Am J Hum Biol; 2013 Dec; 25(6):713-8. PubMed ID: 24130145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.